Latest news with #Flyrcado
Business Wire
30-07-2025
- Business
- Business Wire
GE HealthCare reports second quarter 2025 financial results
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the second quarter ended June 30, 2025. GE HealthCare President and CEO Peter Arduini said, 'We were pleased with solid orders and revenue performance in the second quarter across all segments, reflecting healthy customer investment in capital equipment. We also reported strong earnings performance while leveraging our lean capabilities and demonstrating progress on tariff mitigation. Overall, we believe we are driving long-term value through our strategic priorities and are well positioned operationally.' Second quarter 2025 total company financial performance Revenues of $5.0 billion increased 3% reported and 2% on an Organic* basis year-over-year. Revenue growth was driven by strength in the U.S. and Europe, the Middle East and Africa. Total company book-to-bill was 1.07 times. Total company orders increased 3% organically year-over-year. Net income attributable to GE HealthCare was $486 million versus $428 million for the prior year, and Adjusted EBIT* was $729 million versus $742 million. Net income margin was 9.7% versus 8.9% for the prior year, up 80 basis points (bps) with lower tax and interest expense. Adjusted EBIT margin* was 14.6% versus 15.3%, down 80 bps, impacted by tariffs, partially offset by benefits from productivity and volume. Diluted EPS was $1.06 versus $0.93, up $0.13 from the prior year. Adjusted EPS* was $1.06 versus $1.00, up $0.06 from the prior year as both measures saw lower tax and interest expense. Cash flow from operating activities was $94 million, up $213 million year-over-year. Free cash flow* was $7 million, up $189 million year-over-year. Second quarter 2025 segment financial performance (Unaudited) Growth and innovation Mr. Arduini continued, 'Our differentiated capabilities in nuclear medicine position us to lead in this emerging field across disease states. In the second quarter, we saw increased demand for our radiopharmaceutical products, including Vizamyl, Cerianna and Flyrcado, and we secured our largest-ever order of Omni Legend PET systems in the U.S.' Recent innovation and commercial highlights 2025 guidance Today, the Company raises 2025 full-year guidance, reflective of healthy capital investment trends, operational execution and changes in tariff rates, as follows: Organic revenue growth* of approximately 3% year-over-year; this compares to previous Organic revenue growth* guidance of 2% to 3% Adjusted EBIT margin* of 15.2% to 15.4%, reflecting a decline of 110 bps to 90 bps versus 2024 Adjusted EBIT margin* of 16.3%; this compares to previous Adjusted EBIT margin* guidance of 14.2% to 14.4% Adjusted effective tax rate (ETR)* in the range of 20% to 21%; this compares to previous Adjusted ETR* guidance of 21% to 22% Adjusted EPS* in the range of $4.43 to $4.63, which includes approximately $0.45 of tariff impact versus 2024 Adjusted EPS* of $4.49; this compares to previous Adjusted EPS* guidance in the range of $3.90 to $4.10 Free cash flow* of at least $1.4 billion; this compares to previous Free cash flow* guidance of at least $1.2 billion Tariff assumptions for updated guidance: Bilateral U.S. and China tariffs introduced this year continue and will rise on August 12, 2025 (to a rate of 54% for U.S. tariffs imposed on goods imported from China to the U.S. and to 34% for Chinese tariffs on goods exported from the U.S. to China); U.S. reciprocal rate on EU and Japan products at 15% effective August 1, 2025; tariffs increase for goods imported from Mexico (to 30%) and from Canada (to 35%) on August 1, 2025 and USMCA exemptions for eligible imports continue; U.S. reciprocal tariffs on all other impacted geographies return to pre-pause levels on August 1, 2025, including other increases formally communicated by letter (>10%); excludes potential Section 232 tariff impact. The Company provides its outlook on a non-GAAP basis. Refer to the Non-GAAP financial measures in outlook section below for more details. Financial rounding Certain columns and rows in this document may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts. Financial statements Condensed Consolidated Statements of Income (Unaudited) For the three months ended June 30 For the six months ended June 30 (In millions, except per share amounts) 2025 2024 2025 2024 Sales of products $ 3,263 $ 3,207 $ 6,380 $ 6,253 Sales of services 1,743 1,632 3,404 3,237 Total revenues 5,007 4,839 9,784 9,489 Cost of products 2,160 2,045 4,122 4,012 Cost of services 863 792 1,665 1,574 Gross profit 1,985 2,002 3,997 3,904 Selling, general, and administrative 1,029 1,067 2,069 2,105 Research and development 302 327 646 651 Total operating expenses 1,331 1,395 2,714 2,756 Operating income 654 608 1,283 1,148 Interest and other financial charges – net 113 131 224 254 Non-operating benefit (income) costs (73 ) (101 ) (148 ) (204 ) Other (income) expense – net 1 (1 ) (98 ) 8 Income before income taxes 613 578 1,304 1,090 Benefit (provision) for income taxes (113 ) (143 ) (216 ) (267 ) Net income 500 435 1,088 823 Net (income) loss attributable to noncontrolling interests (14 ) (7 ) (39 ) (21 ) Net income attributable to GE HealthCare $ 486 $ 428 $ 1,049 $ 802 Earnings per share attributable to GE HealthCare: Basic $ 1.06 $ 0.94 $ 2.30 $ 1.76 Diluted 1.06 0.93 2.29 1.75 Weighted-average number of shares outstanding: Basic 457 457 457 456 Diluted 458 459 459 459 Expand Condensed Consolidated Statements of Financial Position (Unaudited) As of (In millions, except share and per share amounts) December 31, 2024 Cash, cash equivalents, and restricted cash $ 3,763 $ 2,889 Receivables – net of allowances of $107 and $103 3,562 3,566 Inventories 2,283 1,939 Contract and other deferred assets 1,062 974 All other current assets 638 532 Current assets 11,308 9,901 Property, plant, and equipment – net 2,962 2,550 Goodwill 13,417 13,136 Other intangible assets – net 1,220 1,078 Deferred income taxes 4,517 4,474 All other non-current assets 2,076 1,950 Total assets $ 35,500 $ 33,089 Short-term borrowings $ 2,005 $ 1,502 Accounts payable 2,975 3,035 Contract liabilities 1,979 1,943 Current compensation and benefits 1,364 1,521 All other current liabilities 1,426 1,552 Current liabilities 9,748 9,553 Long-term borrowings 8,270 7,449 Non-current compensation and benefits 5,351 5,583 Deferred income taxes 173 56 All other non-current liabilities 2,005 1,796 Total liabilities 25,548 24,437 Commitments and contingencies Redeemable noncontrolling interests 220 188 Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 458,275,427 shares issued as of June 30, 2025; 457,246,971 shares issued as of December 31, 2024 5 5 Treasury stock, at cost, 1,718,413 shares as of June 30, 2025 and 291,053 shares as of December 31, 2024 (125 ) (25 ) Additional paid-in capital 6,628 6,583 Retained earnings 4,295 3,262 Accumulated other comprehensive income (loss) – net (1,090 ) (1,379 ) Total equity attributable to GE HealthCare 9,712 8,446 Noncontrolling interests 21 18 Total equity 9,733 8,464 Total liabilities, redeemable noncontrolling interests, and equity $ 35,500 $ 33,089 Expand Condensed Consolidated Statements of Cash Flows (Unaudited) For the six months ended June 30 (In millions) 2025 2024 Net income $ 1,088 $ 823 Adjustments to reconcile Net income to Cash from (used for) operating activities Depreciation of property, plant, and equipment 138 137 Amortization of intangible assets 146 160 Gain on remeasurement of Nihon Medi-Physics equity method investment (97 ) — Net periodic postretirement benefit plan (income) expense (138 ) (180 ) Postretirement plan contributions (182 ) (170 ) Share-based compensation 56 70 Provision for income taxes 216 267 Cash paid during the year for income taxes (270 ) (287 ) Changes in operating assets and liabilities, excluding the effects of acquisitions: Receivables 185 126 Inventories (188 ) (116 ) Contract and other deferred assets (48 ) 12 Accounts payable (113 ) (97 ) Contract liabilities (23 ) (20 ) Current compensation and benefits (207 ) (266 ) All other operating activities – net (218 ) (161 ) Cash from (used for) operating activities 344 300 Cash flows – investing activities Additions to property, plant and equipment and internal-use software (238 ) (209 ) Purchases of businesses, net of cash acquired (279 ) (259 ) Purchases of investments (28 ) (30 ) All other investing activities – net (84 ) (39 ) Cash from (used for) investing activities (630 ) (537 ) Cash flows – financing activities Net increase (decrease) in borrowings (maturities of 90 days or less) 1 — Newly issued debt, net of debt issuance costs (maturities longer than 90 days) 1,493 1 Repayments and other reductions (maturities longer than 90 days) (261 ) (156 ) Dividends paid to stockholders (32 ) (28 ) Repurchase of common stock (100 ) — Proceeds from stock issued under employee benefit plans 21 24 Taxes paid related to net share settlement of equity awards (33 ) (48 ) All other financing activities – net (15 ) (4 ) Cash from (used for) financing activities 1,075 (210 ) Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash 84 (41 ) Increase (decrease) in cash, cash equivalents, and restricted cash 873 (488 ) Cash, cash equivalents, and restricted cash at beginning of year 2,893 2,506 Cash, cash equivalents, and restricted cash at end of period $ 3,766 $ 2,018 Supplemental disclosure of cash flows information Cash paid during the year for interest $ (260 ) $ (274 ) Non-cash investing activities Acquired but unpaid property, plant, and equipment $ 90 $ 76 Expand Non-GAAP financial measures The non-GAAP financial measures presented in this press release are supplemental measures of GE HealthCare's performance and its liquidity that the Company believes will help investors understand its financial condition, cash flows, and operating results, and assess its future prospects. When read in conjunction with the Company's U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in GE HealthCare's underlying businesses and can be used by management as one basis for making financial, operational, and planning decisions. Descriptions of the reported non-GAAP measures are included below. The Company reports Organic revenue and Organic revenue growth rate to provide management and investors with additional understanding and visibility into the underlying revenue trends of the Company's established, ongoing operations, as well as provide insights into overall demand for its products and services. To calculate these measures, the Company excludes the effect of acquisitions, dispositions, and foreign currency rate fluctuations. The Company reports EBIT, Adjusted EBIT, Adjusted EBIT margin, Adjusted net income, and Adjusted earnings per share to provide management and investors with additional understanding of its business by highlighting the results from ongoing operations and the underlying profitability factors, on a normalized basis. To calculate these measures the Company excludes, and reflects in the detailed reconciliations below, the following adjustments as applicable: Interest and other financial charges – net, Net (income) loss attributable to noncontrolling interests, Non-operating benefit (income) costs, Benefit (provision) for income taxes and certain tax related adjustments, and certain non-recurring and/or non-cash items. GE HealthCare may from time to time consider excluding other non-recurring items to enhance comparability between periods. Adjusted EBIT margin is calculated by taking Adjusted EBIT divided by Total revenues for the same period. The Company reports Adjusted tax expense and Adjusted ETR to provide management and investors with a better understanding of the normalized tax rate applicable to the business and provide more consistent comparability across periods. Adjusted tax expense excludes the income tax related to the pre-tax income adjustments included as part of Adjusted net income and certain income tax adjustments, such as adjustments to deferred tax assets or liabilities. The Company may from time to time consider excluding other non-recurring tax items to enhance comparability between periods. Adjusted ETR is Adjusted tax expense divided by income before income taxes less the pre-tax income adjustments referenced above. The Company reports Free cash flow and Free cash flow conversion to provide management and investors with an important measure of the ability to generate cash on a normalized basis and provide insight into the Company's flexibility to allocate capital. Free cash flow is Cash from (used for) operating activities – continuing operations including cash flows related to the additions and dispositions of property, plant, and equipment ('PP&E') and additions of internal-use software. Free cash flow does not represent residual cash flows available for discretionary expenditures, due to the fact that the measure does not deduct the capital required for debt repayments. Free cash flow conversion is calculated by taking Free cash flow divided by Adjusted net income. Management recognizes that these non-GAAP financial measures have limitations, including that they may be calculated differently by other companies or may be used under different circumstances or for different purposes. In order to compensate for the discussed limitations, management does not consider these measures in isolation from or as alternatives to the comparable financial measures determined in accordance with U.S. GAAP. The detailed reconciliations of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure are provided below, and no single financial measure should be relied on to evaluate our business. Unaudited For the three months ended June 30 For the six months ended June 30 ($ in millions) 2025 2024 % change 2025 2024 % change Imaging revenues $ 2,204 $ 2,171 2 % $ 4,344 $ 4,233 3 % Less: Acquisitions(1) — — 14 — Less: Dispositions(2) — — — — Less: Foreign currency exchange 15 — (24 ) — Imaging Organic revenue* $ 2,189 $ 2,171 1 % $ 4,354 $ 4,233 3 % AVS revenues $ 1,289 $ 1,249 3 % $ 2,529 $ 2,475 2 % Less: Acquisitions(1) — — — — Less: Dispositions(2) — — — — Less: Foreign currency exchange 11 — (8 ) — AVS Organic revenue* $ 1,279 $ 1,249 2 % $ 2,537 $ 2,475 2 % PCS revenues $ 778 $ 772 1 % $ 1,531 $ 1,519 1 % Less: Acquisitions(1) — — — — Less: Dispositions(2) — — — — Less: Foreign currency exchange 3 — (3 ) — PCS Organic revenue* $ 775 $ 772 — % $ 1,535 $ 1,519 1 % PDx revenues $ 729 $ 639 14 % $ 1,362 $ 1,238 10 % Less: Acquisitions(1) 53 2 53 2 Less: Dispositions(2) — — — — Less: Foreign currency exchange 7 — (6 ) — PDx Organic revenue* $ 669 $ 637 5 % $ 1,315 $ 1,236 6 % Other revenues $ 6 $ 9 (39 )% $ 19 $ 24 (22 )% Less: Acquisitions(1) — — — — Less: Dispositions(2) — — — — Less: Foreign currency exchange — — — — Other Organic revenue* $ 6 $ 9 (41 )% $ 19 $ 24 (22 )% Total revenues $ 5,007 $ 4,839 3 % $ 9,784 $ 9,489 3 % Less: Acquisitions(1) 53 2 67 2 Less: Dispositions(2) — — — — Less: Foreign currency exchange 36 — (42 ) — Organic revenue* $ 4,917 $ 4,837 2 % $ 9,759 $ 9,487 3 % (1) Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction. (2) Represents revenues attributable to dispositions for the four quarters preceding the disposition date. Expand Adjusted EBIT* Unaudited For the three months ended June 30 For the six months ended June 30 ($ in millions) 2025 2024 % change 2025 2024 % change Net income attributable to GE HealthCare $ 486 $ 428 13 % $ 1,049 $ 802 31 % Add: Interest and other financial charges – net 113 131 224 254 Add: Non-operating benefit (income) costs (73 ) (101 ) (148 ) (204 ) Less: Benefit (provision) for income taxes (113 ) (143 ) (216 ) (267 ) Less: Net (income) loss attributable to noncontrolling interests (14 ) (7 ) (39 ) (21 ) EBIT* $ 653 $ 608 7 % $ 1,380 $ 1,140 21 % Add: Restructuring costs(1) 18 29 40 68 Add: Acquisition and disposition-related charges (benefits)(2) 7 (3 ) 15 (3 ) Add: Spin-Off and separation costs(3) 5 67 29 126 Add: (Gain) loss on business and asset dispositions(4) 5 — (5 ) — Add: Amortization of acquisition-related intangible assets 40 35 75 66 Add: Investment revaluation (gain) loss(5) 1 6 (92 ) 26 Adjusted EBIT* $ 729 $ 742 (2 )% $ 1,443 $ 1,423 1 % Net income margin 9.7 % 8.9 % 80 bps 10.7 % 8.5 % 230 bps Adjusted EBIT margin* 14.6 % 15.3 % (80) bps 14.8 % 15.0 % (20) bps (1) Consists of severance, facility closures, and other charges associated with restructuring programs. (2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions. (3) Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. (4) Consists of gains and losses resulting from the sale of assets and investments. (5) Primarily relates to valuation adjustments for equity investments and for the six months ended June 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction. Expand Adjusted Net Income* Unaudited For the three months ended June 30 For the six months ended June 30 ($ in millions) 2025 2024 % change 2025 2024 % change Net income attributable to GE HealthCare $ 486 $ 428 13 % $ 1,049 $ 802 31 % Add: Non-operating benefit (income) costs (73 ) (101 ) (148 ) (204 ) Add: Restructuring costs(1) 18 29 40 68 Add: Acquisition and disposition-related charges (benefits)(2) 7 (3 ) 15 (3 ) Add: Spin-Off and separation costs(3) 5 67 34 126 Add: (Gain) loss on business and asset dispositions(4) 5 — (5 ) — Add: Amortization of acquisition-related intangible assets 40 35 75 66 Add: Investment revaluation (gain) loss(5) 1 6 (92 ) 26 Add: Tax effect of reconciling items(6) (1 ) (10 ) (1 ) (24 ) Add: Spin-Off and other tax adjustments(7) — 9 (18 ) 14 Adjusted net income* $ 487 $ 459 6 % $ 951 $ 872 9 % (1) Consists of severance, facility closures, and other charges associated with restructuring programs. (2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions. (3) Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. An adjustment is included to eliminate the associated impact on Net (income) loss attributable to noncontrolling interests for applicable costs that impact earnings attributable to noncontrolling interests. (4) Consists of gains and losses resulting from the sale of assets and investments. (5) Primarily relates to valuation adjustments for equity investments and for the six months ended June 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction. (6) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction. (7) Consists of certain income tax adjustments, including the release of income tax reserves in a foreign jurisdiction for tax years which are no longer subject to an assessment from the local taxing authorities, discrete tax impacts resulting from the Spin-Off and separation from GE, and tax impacts of the NMP acquisition. As of the third quarter of 2024 this line additionally includes discrete tax impacts resulting from the Spin-Off and separation from GE previously reported under Tax effect of reconciling items. Expand Adjusted Earnings Per Share* Unaudited For the three months ended June 30 For the six months ended June 30 (In dollars, except shares outstanding presented in millions) 2025 2024 $ change 2025 2024 $ change Diluted earnings per share $ 1.06 $ 0.93 $ 0.13 $ 2.29 $ 1.75 $ 0.54 Add: Non-operating benefit (income) costs (0.16 ) (0.22 ) (0.32 ) (0.44 ) Add: Restructuring costs(1) 0.04 0.06 0.09 0.15 Add: Acquisition and disposition-related charges (benefits)(2) 0.02 (0.01 ) 0.03 (0.01 ) Add: Spin-Off and separation costs(3) 0.01 0.15 0.07 0.28 Add: (Gain) loss on business and asset dispositions(4) 0.01 — (0.01 ) — Add: Amortization of acquisition-related intangible assets 0.09 0.08 0.16 0.14 Add: Investment revaluation (gain) loss(5) 0.00 0.01 (0.20 ) 0.06 Add: Tax effect of reconciling items(6) (0.00 ) (0.02 ) (0.00 ) (0.05 ) Add: Spin-Off and other tax adjustments(7) — 0.02 (0.04 ) 0.03 Adjusted earnings per share* $ 1.06 $ 1.00 $ 0.06 $ 2.07 $ 1.90 $ 0.17 Diluted weighted-average shares outstanding 458 459 459 459 (1) Consists of severance, facility closures, and other charges associated with restructuring programs. (2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions. (3) Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. An adjustment is included to eliminate the associated impact on Net (income) loss attributable to noncontrolling interests for applicable costs that impact earnings attributable to noncontrolling interests. (4) Consists of gains and losses resulting from the sale of assets and investments. (5) Primarily relates to valuation adjustments for equity investments and for the six months ended June 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction. (6) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction. (7) Consists of certain income tax adjustments, including the release of income tax reserves in a foreign jurisdiction for tax years which are no longer subject to an assessment from the local taxing authorities, discrete tax impacts resulting from the Spin-Off and separation from GE, and tax impacts of the NMP acquisition. As of the third quarter of 2024 this line additionally includes discrete tax impacts resulting from the Spin-Off and separation from GE previously reported under Tax effect of reconciling items. Expand Adjusted Tax Expense* and Adjusted ETR* Unaudited For the three months ended June 30 For the six months ended June 30 ($ in millions) 2025 2024 2025 2024 Benefit (provision) for income taxes $ (113 ) $ (143 ) $ (216 ) $ (267 ) Add: Tax effect of reconciling items(1) (1 ) (10 ) (1 ) (24 ) Add: Spin-Off and other tax adjustments(2) — 9 (18 ) 14 Adjusted tax expense* $ (114 ) $ (144 ) $ (235 ) $ (277 ) Effective tax rate 18.4 % 24.7 % 16.6 % 24.5 % Adjusted effective tax rate* 18.5 % 23.6 % 19.3 % 23.7 % (1) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction. (2) Consists of certain income tax adjustments, including the release of income tax reserves in a foreign jurisdiction for tax years which are no longer subject to an assessment from the local taxing authorities, discrete tax impacts resulting from the Spin-Off and separation from GE, and tax impacts of the NMP acquisition. As of the third quarter of 2024 this line additionally includes discrete tax impacts resulting from the Spin-Off and separation from GE previously reported under Tax effect of reconciling items. Expand Non-GAAP financial measures in outlook GE HealthCare calculates forward-looking non-GAAP financial measures, including Organic revenue growth, Adjusted EBIT margin, Adjusted ETR, Adjusted EPS, and Free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. GE HealthCare does not provide reconciliations of these forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or dispositions, timing and magnitude of restructuring activities, and revaluation of strategic investments, amongst other items. The timing and amounts of these items are uncertain and could have a substantial impact on GE HealthCare's results in accordance with GAAP. Key performance indicators Management uses the following metrics to provide a leading indicator of current business demand from customers for products and services. Organic orders growth: Rate of change period-over-period of contractual commitments with customers to provide specified goods or services for an agreed upon price, and excluding the effects of: (1) recent acquisitions and dispositions with less than a full year of comparable orders; and (2) foreign currency exchange rate fluctuations in order to present orders on a constant currency basis. Book-to-bill: Total orders divided by Total revenues within a given financial period (e.g., quarter or FY). Conference call and webcast information GE HealthCare will discuss its results during its live earnings call today, July 30, 2025 at 8:30 am ET/7:30 am CT. The webcast and accompanying slide presentation containing financial information can be accessed by visiting the investor section of the website at An archived version of the webcast will be available on the website after the call. Forward-looking statements This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as 'will,' 'expect,' 'may,' 'would,' 'could,' 'plan,' 'believe,' 'anticipate,' 'intend,' 'estimate,' 'potential,' 'position,' 'forecast,' 'target,' 'guidance,' 'outlook,' and similar expressions. These forward-looking statements may include, but are not limited to, statements about the Company's business and expected financial performance, financial condition, and results of operations, including revenue, revenue growth, profit, taxes, earnings per share, and cash flows, and the Company's outlook; the impacts of macroeconomic and market conditions, including the impact of tariffs and other trade restrictions, and volatility on the Company's business, operations, financial results, and financial position and on supply chains and the world economy; and the Company's strategy, innovation, and investments. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company's control. Factors that could cause the Company's actual results to differ materially from those described in its forward-looking statements include, but are not limited to, operating in highly competitive markets; global geopolitical and economic instability, including as a result of changes in trade and tariff policy, and international conflicts and tensions, including between Ukraine and Russia and in the Middle East; public health crises, epidemics, and pandemics, and their effects on the Company's business; changes in third-party and government reimbursement processes, rates, and contractual relationships, including related to government shutdowns, and changes in the mix of public and private payers; demand for the Company's products, services, or solutions and factors that affect that demand; developments in the market in China; the Company's ability to control increases in healthcare costs and any subsequent effect on demand for the Company's products, services, or solutions; the Company's ability to successfully complete strategic transactions; the impacts related to the Company's increasing focus on and investment in cloud, edge computing, artificial intelligence, and software offerings; management of the Company's supply chain and the Company's ability to cost-effectively secure the materials it needs to operate its business; disruptions in the Company's operations; the actions or inactions of third parties with whom the Company partners and the various collaboration, licensing, and other partnerships and alliances the Company has with third parties; the impact of potential information technology, cybersecurity, or data security breaches; maintenance and protection of the Company's intellectual property rights, as well as maintenance of successful research and development efforts with respect to commercially successful products and technologies; the Company's ability to attract and/or retain key personnel and qualified employees; environmental, social, and governance matters; compliance with the various legal, regulatory, tax, privacy, and other laws to which the Company is subject, such as the Foreign Corrupt Practices Act and similar anti-corruption and anti-bribery laws globally, and related changes, claims, inquiries, investigations, or actions; the impact of potential product liability claims; the Company's level of indebtedness, the Company's general ability to comply with covenants under its debt instruments, and any related effect on its business. Please also see Item 1A, 'Risk Factors' of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company's actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. * Non-GAAP financial measure.
Yahoo
25-06-2025
- Business
- Yahoo
The 5 Most Interesting Analyst Questions From GE HealthCare's Q1 Earnings Call
GE HealthCare's first quarter results came in above Wall Street expectations, as the company delivered broad-based revenue growth across all business segments. Management credited strong U.S. demand for imaging equipment—particularly in cardiology and oncology—as well as robust order activity and backlog expansion, for the positive momentum. CEO Peter Arduini highlighted, 'Record double-digit orders growth as a standalone company was driven by strength in the U.S. market, where we see customers prioritizing investments in imaging products.' The company also noted early market share gains and strong customer engagement as key contributors to the quarter's performance. Is now the time to buy GEHC? Find out in our full research report (it's free). Revenue: $4.78 billion vs analyst estimates of $4.66 billion (2.8% year-on-year growth, 2.5% beat) Adjusted EPS: $1.01 vs analyst estimates of $0.91 (10.6% beat) Adjusted EBITDA: $826.9 million vs analyst estimates of $794.4 million (17.3% margin, 4.1% beat) Management lowered its full-year Adjusted EPS guidance to $4 at the midpoint, a 14.5% decrease Operating Margin: 13.2%, up from 11.6% in the same quarter last year Organic Revenue rose 4.1% year on year (-0.5% in the same quarter last year) Market Capitalization: $32.96 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Larry Biegelsen (Wells Fargo) asked about the timing and magnitude of tariff impacts and the pace of mitigation. CFO Jay Saccaro explained that most mitigation will be realized in the second half of the year and further improvements are targeted for 2026. Jason Bednar (Piper Sandler) inquired whether tariff mitigation actions were accelerated from long-range plans. CEO Peter Arduini clarified that while some actions were advanced, the broader margin and growth outlook remains unchanged. Vijay Kumar (Evercore ISI) questioned the proportion of tariff headwinds tied to U.S.-China trade and the potential upside if tariffs are eased. Saccaro detailed that bilateral tariffs account for the majority of the impact and that a rollback could deliver substantial upside to earnings. Robbie Marcus (JPMorgan) requested updates on Flyrcado's launch and potential anti-dumping risks in China. Arduini confirmed Flyrcado is on track and stated that recent anti-dumping investigations are not expected to materially impact the business. Joanne Wuensch (Citi) probed the durability of hospital capital spending and the timeline for photon counting CT approval. Saccaro reported continued strength in U.S. and European demand, while Arduini reiterated that photon counting CT remains on schedule for regulatory submission. In the coming quarters, the StockStory team will closely monitor (1) the pace and effectiveness of GE HealthCare's tariff mitigation strategies, (2) progress on new product rollouts, including Flyrcado and photon counting CT, and (3) sustainability of order growth and backlog conversion, particularly in key markets like China and the U.S. Updates on supply chain adjustments and the impact of shifting trade policy will also be important indicators of execution. GE HealthCare currently trades at $71.99, up from $68.09 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
24-06-2025
- Business
- Yahoo
GE HealthCare's Flyrcado Sets New Benchmark in Cardiac PET Imaging
GE HealthCare GEHC recently unveiled new advancements in precision cardiac care at the 2025 SNMMI annual meeting in New Orleans, with a spotlight on Flyrcado—its FDA-approved Positron Emission Tomography (PET) imaging agent for myocardial perfusion imaging (MPI). As cardiovascular disease continues to rise globally, GEHC emphasized Flyrcado's role in enabling more accurate diagnosis, treatment planning, and broader access to personalized cardiac care through advanced molecular imaging. Flyrcado reflects GEHC's broader focus on advancing precision cardiac care through molecular imaging. It plays a key role in enabling earlier disease detection, personalizing treatment strategies, and monitoring therapy response or disease progression. The company highlighted Flyrcado at the 2025 SNMMI annual meeting, reinforcing its commitment to delivering advanced diagnostic tools that improve outcomes for the growing population at risk of cardiovascular disease. GEHC's Flyrcado (flurpiridaz F 18) is a fluorine-18 PET MPI agent developed for patients with known or suspected coronary artery disease. Flyrcado has a longer half-life of approximately 110 minutes. This allows for centralized production and broad distribution. For the first time, it also enables the practical integration of exercise stress testing with cardiac PET imaging. Compatible with GEHC's Omni Legend PET/CT and other systems, the agent is designed to support detailed assessment of myocardial perfusion, ischemia, and infiltrative cardiomyopathies. Recently launched in select U.S. markets, Flyrcado received CMS pass-through status effective April 1 and is supported by a specific HCPCS billing code. The agent is now covered by all seven Medicare Administrative Contractors and by more than 50% of commercial insurers under updated national and regional cardiac PET policies. Coverage has expanded beyond hospital outpatient settings, and GEHC has established a dedicated Flyrcado Support Center to assist providers with coding, benefits investigations, and claims submissions. Shares of the company closed flat at $71.16 yesterday following the announcement. In the year-to-date period, GEHC shares have lost 9% against the industry's 4% growth. The S&P 500 increased 0.8% in the same time frame. Flyrcado positions GEHC for long-term growth by expanding its presence in the high-value molecular imaging market, where demand for precision cardiac diagnostics is rising. With broad payer coverage, CMS reimbursement, and compatibility with existing PET/CT systems, Flyrcado can accelerate the shift from SPECT to PET imaging—unlocking recurring revenue from both radiopharmaceutical sales and imaging hardware. As adoption scales beyond hospitals in outpatient settings, Flyrcado strengthens GEHC's precision care portfolio and supports its strategy to drive margin expansion through innovation-led, high-utility diagnostics. Meanwhile, GEHC currently has a market capitalization of $32.64 billion and carries a Zacks Rank #4 (Sell). In the last reported quarter, GEHC delivered an earnings surprise of 10.9%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Image Source: Zacks Investment Research Koninklijke Philips PHG has recently accelerated its cardiac imaging leadership through advanced AI integration in both CT and ultrasound modalities. In January 2025, the company launched the AI-enabled CT 5300, a 128-slice CT system equipped with AI-powered cardiac motion correction and reconstruction at AOCR 2025, enhancing image clarity, speeding workflows, and reducing radiation exposure in cardiac scans. Complementing this, Philips' Spectral CT 7500 continues to deliver 'always-on' dual-layer spectral imaging, FDA-cleared for 4D respiratory-gated applications, offering clinicians the ability to assess coronary arteries and myocardial perfusion with superior diagnostic confidence during a single, swift scan. Nano-X Imaging Ltd. NNOX through its AI imaging division received FDA 510(k) clearance for HealthCCSng V2.0 in August 2024, an AI-powered solution that automatically quantifies coronary artery calcium (CAC) from routine non-gated chest CT scans, adding a 'zero calcium' category and numerical scoring for more nuanced risk stratification. At SCCT 2024, real-world studies were showcased, including evidence from Brigham & Women's Hospital demonstrating that HealthCCSng flagged incidental CAC in more than 50% of immune-mediated inflammatory disease patients highlighting its potential for early detection and preventive care across broad clinical settings. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report Nano-X Imaging Ltd. (NNOX) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Wire
23-06-2025
- Health
- Business Wire
GE HealthCare enhances cardiac diagnostics with innovative molecular imaging solutions showcased at SNMMI 2025
CHICAGO--(BUSINESS WIRE)--GE HealthCare's commitment to advancing precision care in cardiology through innovative molecular imaging solutions is on full display at this week's Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana. 'Flyrcado represents one of the most significant advancements in nuclear cardiology in decades,' shares Marcelo Fernando DiCarli, MD, Chief, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Executive Director, Cardiovascular Share As cardiovascular disease (CVD) continues to rise globally, i the need for advanced diagnostic technologies becomes increasingly critical. GE HealthCare's molecular imaging technologies – including positron emission tomography-computed tomography (PET/CT) and single-photon emission computed tomography-computed tomography (SPECT/CT) – and radiopharmaceuticals – namely its Flyrcado™ (flurpiridaz F 18) injection – play a crucial role in cardiac care by providing detailed insights into biological processes beyond conventional imaging. These advanced imaging techniques enable early diagnosis, precise assessment of myocardial perfusion and ischemia, and evaluation of infiltrative cardiomyopathies. By identifying specific pathologic processes, molecular imaging helps tailor treatments to individual patients, with the aim to enhance the effectiveness of therapies and improving prognosis. Additionally, it allows for monitoring treatment responses and disease progression, ultimately helping contribute to better patient outcomes. ii 'Flyrcado represents one of the most significant advancements in nuclear cardiology in decades,' shares Marcelo Fernando DiCarli, MD, Chief, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Executive Director, Cardiovascular Imaging Program, Departments of Radiology and Medicine, Brigham and Women's Hospital. 'For the first time in nearly 20 years, we have a new PET myocardial perfusion tracer that brings the latest imaging technology within reach for patients across the U.S. The image quality is exceptional, and its use has the potential to reduce unnecessary invasive procedures by improving diagnostic confidence. I've found it to be a valuable addition to our clinical practice, enabling more personalized treatment strategies and better patient outcomes. The excitement across the cardiology community is evident as we enter a new era in precision cardiac care.' GE HealthCare's Flyrcado injection, a first-of-its-kind F 18-unit dose PET myocardial perfusion imaging (MPI) agent for patients with known or suspected coronary artery disease (CAD), helps clinicians deliver higher diagnostic efficacy compared to SPECT MPI, the predominant procedure used in nuclear cardiology today. Recently launched in select U.S. markets, Flyrcado's availability aligns with its receipt of CMS pass-through status, effective April 1, which includes a drug-specific HCPCS billing code to support efficient coding and Medicare coverage. In addition, Flyrcado is now covered by all seven Medicare Administrative Contractors (MACs) at either invoice price or better, depending on the site of care. More than 50% of commercially insured beneficiaries are now covered under updated national and regional cardiac PET policies that include Flyrcado as a covered benefit—marking significant progress in expanding access beyond the hospital outpatient setting. Further expansion is expected in the second half of the year as additional payors complete their policy reviews. To support this evolving access landscape, GE HealthCare has launched the Flyrcado Support Center (800-729-0701) to assist customers with benefits investigations, coding, coverage, and claims submissions. 'With coverage now in place for all traditional Medicare beneficiaries, along with updated PET coverage policies in place for more than half of the nation's commercially insured beneficiaries, millions of Americans—many at risk for or living with coronary artery disease, the leading cause of death in the U.S.—will have greater access to this innovative technology,' said Eric Ruedinger, Vice President and General Manager of GE HealthCare's Pharmaceutical Diagnostics division for the U.S. and Canada. 'Flyrcado represents a significant advancement in cardiac care over SPECT imaging, offering clinicians a new, highly effective diagnostic tool to support more timely and personalized care for patients with known or suspected coronary artery disease.' Flyrcado can be imaged with a range of PET/CT systems, including GE HealthCare's Omni Legend, offering clinicians flexibility in integrating this innovative tracer into their existing imaging workflows. With Flyrcado, clinicians have the first practical opportunity to combine exercise stress testing with cardiac PET imaging for CAD, providing a highly effective protocol for evaluating ischemia in patients. Beyond Flyrcado, Omni Legend enables exceptional cardiac diagnostics, accommodating a range of tracers – including fast decay and emerging tracers. Representing a scalable PET/CT platform designed to evolve with healthcare system needs across care areas with shorter scan times and lower doses, iii it continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. iv GE HealthCare is also proud to provide its StarGuide and Aurora SPECT/CT systems, designed to capture gamma rays emitted by radioactive tracers. Both systems offer exceptional image quality and scan time efficiency, supporting clinicians in making confident diagnoses. These features make SPECT/CT a valuable tool in cardiac care, providing comprehensive views of both physiological and structural aspects of diseases. Additional solutions from GE HealthCare's MIM Software are also available to enable multi-modality viewing and fusion of cardiac images and offer integration pathways for cardiac analysis. A devoted provider of cardiology solutions, GE HealthCare supports the continuum of care and personalized treatments for the world's largest hospitals to the smallest clinics and beyond the walls of the clinician's office. With a vast and diversified portfolio, GE HealthCare offers healthcare professionals a breadth of solutions from early detection and diagnosis, to planning, intervention, and monitoring to help clinicians deliver better patient outcomes in cardiology care today and for the future. For more information on GE HealthCare's innovative portfolio of molecular solutions for cardiology, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. Forward-looking statements This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as 'will,' 'expect,' 'may,' 'would,' 'could,' 'plan,' 'believe,' 'anticipate,' 'intend,' 'potential,' and similar expressions. These forward-looking statements may include, but are not limited to, statements about Flyrcado and GE HealthCare Technologies Inc.'s (the 'Company's') performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company's actual results to differ materially from those described in its forward-looking statements include, but are not limited to, uncertainties regarding the commercial success of Flyrcado, the Company's ability to receive pass-through status from the US Centers for Medicaid and Medicare, and decisions by regulatory authorities impacting labeling, manufacturing processes, safety, or other matters that could affect the availability or commercial potential of Flyrcado. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company's actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation. Important Safety Information and Usage of Flyrcado™ (flurpiridaz F 18) injection FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use important safety information Indications and usage FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. Contraindications None Warnings and precautions Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent's prescribing information. Radiation risks: FLYRCADO contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void. Adverse reactions Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia. Use in specific populations Pregnancy There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure. FLYRCADO contains ethanol (a maximum daily dose of 337 mg anhydrous ethanol). If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes associated with ethanol exposure during pregnancy. Lactation Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO administration. Pediatric Use Safety and effectiveness of FLYRCADO in pediatric patients have not been established.
Yahoo
31-03-2025
- Health
- Yahoo
GE HealthCare's Latest Product Launch to Boost Cardiology Care
GE HealthCare Technologies Inc. GEHC recently announced the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the ongoing American College of Cardiology (ACC) Annual Scientific Session & Expo. It also plans to unveil the latest version of CASE (Cardiac Assessment System for Stress Testing), powered by its CardioSoft technology, at the ACC. GE HealthCare also plans to showcase CardIQ Suite (an integrated workflow for the seamless review of calcium scoring and cardiac computed tomography angiography data) and its recently launched AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab editions. GEHC aims to highlight its strategy to leverage AI to help increase efficiency and enable seamless integration of data across the cardiology care pathway by showcasing its latest AI-powered innovations. The latest launch is expected to significantly strengthen GE HealthCare's Cardiology Solutions unit, thus boosting its overall business. Per GE HealthCare's estimates, around six million myocardial perfusion imaging (MPI) procedures are undertaken each year in the United States to show blood flow through the heart muscle and evaluate the presence, extent and degree of myocardial ischemia or infarction. Positron emission tomography (PET) is currently the most effective form of MPI for detecting coronary artery disease (CAD) and is recommended for a wide range of patients, including those considered more challenging to diagnose, over single-photon emission computed tomography (SPECT) MPI. GEHC further stated that the FDA approved Flyrcado for patients with known or suspected CAD in 2024. This is expected to deliver higher diagnostic efficacy, unlike SPECT MPI, the predominant procedure used in nuclear cardiology at present. GE HealthCare's management believes that the launch of Flyrcado represents a significant advancement in cardiac care, providing a new, highly effective diagnostic tool for those with known or suspected CAD. Additionally, Flyrcado has been granted traditional pass-through payment status by the U.S. Centers for Medicare and Medicaid (CMS). The receipt of pass-through status from the CMS, effective April 1, secures a drug-specific Healthcare Common Procedure Coding System or HCPCS billing code and coverage for traditional Medicare beneficiaries. Pass-through payment status will likely enable CMS to provide separate payments for radiopharmaceutical and PET-CT scan, when performed with Flyrcado in the hospital outpatient setting. Per a report by Grand View Research, the global coronary heart disease diagnostic imaging device market was estimated to be $2 billion in 2024 and is anticipated to witness a CAGR of 6.6% between 2025 and 2030. Factors like the increasing prevalence of CAD and the rising adoption of early diagnostic techniques are likely to drive the market. Given the market potential, the latest product availability is expected to provide a significant boost to GE HealthCare's business. This month, GEHC announced the launch of the AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab. The AltiX AI.i edition is expected to enhance efficiency and precision care for multiple types of cardiac procedures. GEHC's peer in the cardiovascular space, Merit Medical Systems, Inc. MMSI, announced the enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in premature infants (PREEMIE study) this month. Per Merit Medical, the Bloom Micro Occluder System was designed as a minimally invasive option for treating hemodynamically significant PDA. The PREEMIE study has been developed to evaluate its safety and efficacy. Last month, Merit Medical reported its fourth-quarter 2024 results, wherein its Cardiovascular unit and all its product categories reported robust revenue growth. Another player and GE HealthCare's peer in the cardiovascular space is Medtronic plc MDT. This month, Medtronic released the two-year positive results of the Small Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international head-to-head comparative trial of transfemoral transcatheter aortic valve replacement. Last month, Medtronic reported its third-quarter fiscal 2025 results, wherein its Cardiovascular Portfolio witnessed a robust revenue uptick on both reported and organic basis. Another renowned peer in the cardiovascular space is Abbott Laboratories ABT. This month, ABT announced the receipt of the CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation. Following this, Abbott has begun commercial PFA cases in the European Union (EU) with physicians who are familiar with the Volt PFA System within its PFA clinical studies. ABT plans to further expand the use of Volt in EU markets throughout the second half of the year. Abbott also announced this month that the FDA has approved an investigational device exemption for its Coronary Intravascular Lithotripsy System to evaluate the treatment of severe calcification in coronary arteries prior to stenting. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
